Losartan Potassium IR Pellets are pharmaceutical-grade immediate-release multiparticulate pellets containing Losartan Potassium as the active pharmaceutical ingredient. They are designed for oral formulation applications where rapid availability of the active ingredient from individual pellet units is required.
Losartan Potassium is identified by CAS Number 124750-99-8, molecular formula C₂₂H₂₂ClKN₆O, and molecular weight 461.0 g/mol. Losartan Potassium is the potassium salt form of Losartan and has well-defined chemical characteristics relevant to pharmaceutical formulation development.
The current SDP pellet product list documents Losartan Potassium IR Pellets in 17%, 20% and 22.5% strengths. These strengths can therefore be presented as SDP product strengths rather than merely commercial market references.
The immediate-release pellet format provides a multiparticulate platform in which active loading, pellet size, physical characteristics, active distribution and dissolution performance can be controlled according to the intended oral formulation.
Losartan Potassium Immediate-Release Pellets are developed as multiple individual pellet units rather than a single-unit formulation. This multiparticulate structure provides flexibility during formulation development and can support consistent downstream processing.
The performance of an immediate-release pellet system can be influenced by the pellet core composition, Losartan Potassium loading, particle-size distribution, porosity, surface characteristics, excipient selection and manufacturing process.
A controlled pellet system can provide consistent physical characteristics and support reproducible handling during capsule filling or other oral formulation operations. Parameters such as active loading, pellet size, density, friability and content uniformity are therefore important considerations during development.
Losartan Potassium IR Pellets are available in 17%, 20% and 22.5% strengths according to the current SDP product list.
These different active-loading levels provide formulation flexibility for customers developing oral multiparticulate products with different active concentration requirements.
The active loading represents the quantity of Losartan Potassium incorporated into the finished pellet system. Active loading can influence pellet composition, excipient ratio, pellet mass, downstream capsule filling and other formulation characteristics.
The multiparticulate structure of Losartan Potassium IR Pellets provides flexibility for oral formulation development. Each pellet functions as an individual unit, while the complete formulation contains a controlled population of pellets with defined physical and chemical characteristics.
Losartan Potassium IR Pellets can be considered for:
The final suitability of the pellets depends on the intended formulation, manufacturing process and applicable finished-product specification.
Capsule filling is an important application of pharmaceutical multiparticulate pellets. Losartan Potassium IR Pellets can be developed with suitable particle-size distribution, density and physical characteristics to support capsule-filling operations.
Consistent pellet characteristics can help support reproducible filling and uniform active distribution. Important physical characteristics may include particle size, bulk density, tapped density, friability, sphericity, moisture content and pellet morphology.
The appropriate physical specifications should be established according to the intended formulation and finished-product requirements.
The release performance of Losartan Potassium IR Pellets depends on formulation and manufacturing design. Important variables can include:
An immediate-release pellet system should be evaluated using an appropriate validated dissolution method. The exact dissolution acceptance criteria are product-specific and should be established for the applicable finished-product specification.
Active loading is a key quality attribute for Losartan Potassium IR Pellets. The specified Losartan Potassium concentration should remain consistent throughout the manufactured batch.
Content uniformity is particularly important in multiparticulate formulations because consistent active distribution helps support reproducible finished-product performance. Appropriate process controls and validated analytical testing can be used to evaluate active distribution and batch consistency.
The active ingredient specification and finished-pellet specification should remain clearly separated. The finished pellet assay should be established around the intended 17%, 20% or 22.5% loading, according to the applicable product specification, rather than using a raw-material assay range as the finished-pellet specification.
High-quality Losartan Potassium Pharmaceutical Pellets can be evaluated through chemical, physical and performance-related characteristics.
Chemical evaluation may include:
Physical evaluation may include:
Performance evaluation may include:
The final acceptance criteria should be based on the applicable finished-product specification.
Losartan Potassium IR Pellets provide a flexible multiparticulate platform for immediate-release formulation development. Formulation developers can evaluate active loading, pellet size, core composition and physical characteristics according to the intended formulation.
The availability of 17%, 20% and 22.5% strengths provides flexibility when developing formulations requiring different active concentrations.
The pellet format can also support process optimization and scale-up by providing defined physical characteristics for downstream manufacturing operations.
For pharmaceutical manufacturers developing oral multiparticulate formulations, consistent pellet characteristics can support reproducible processing, capsule filling and finished-product quality.
Losartan Potassium IR Pellets from Swapnroop are positioned as pharmaceutical-grade multiparticulate pellets for immediate-release formulation and bulk pharmaceutical applications.
Key product advantages include:
As a Losartan Potassium IR Pellets Manufacturer and Supplier in India, Swapnroop can position Losartan Potassium immediate-release pellets for pharmaceutical formulation development, multiparticulate applications, capsule filling and bulk pharmaceutical requirements.
The product range includes 17%, 20% and 22.5% Losartan Potassium IR Pellets, providing formulation flexibility for different active-loading requirements.
Customers searching for Losartan Potassium IR Pellets Manufacturer in India, Losartan Potassium IR Pellets Supplier in India, Losartan Potassium 17% IR Pellets, Losartan Potassium 20% IR Pellets, Losartan Potassium 22.5% IR Pellets, Losartan Potassium Pharmaceutical Pellets, Losartan Potassium Immediate-Release Pellets, Losartan Potassium Multiparticulate Pellets, and Losartan Potassium Pellets for Capsule Filling can be naturally addressed through the product page's topical content.
Losartan Potassium IR Pellets can be supplied in suitable pharmaceutical packaging according to the required:
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |